Zevra Therapeutics (NASDAQ:ZVRA) Issues Earnings Results, Beats Estimates By $0.12 EPS

Zevra Therapeutics (NASDAQ:ZVRA) posted its quarterly earnings data on Wednesday. The company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12, FiscalAI reports. Zevra Therapeutics had a return on equity of 57.42% and a net margin of 78.17%.

Zevra Therapeutics Stock Performance

Shares of ZVRA stock traded up $0.64 on Wednesday, reaching $11.25. The stock had a trading volume of 1,886,785 shares, compared to its average volume of 1,019,225. The stock has a market cap of $665.10 million, a P/E ratio of 8.46 and a beta of 0.88. The company has a debt-to-equity ratio of 0.40, a quick ratio of 5.63 and a current ratio of 5.68. The company has a 50 day simple moving average of $9.63 and a 200 day simple moving average of $9.25. Zevra Therapeutics has a 1 year low of $7.16 and a 1 year high of $13.16.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ZVRA. Russell Investments Group Ltd. lifted its position in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares in the last quarter. Creative Planning purchased a new position in Zevra Therapeutics during the second quarter valued at $92,000. Qube Research & Technologies Ltd purchased a new position in Zevra Therapeutics during the second quarter valued at $99,000. Finally, Quarry LP purchased a new position in Zevra Therapeutics during the third quarter valued at $103,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZVRA has been the topic of several recent analyst reports. Weiss Ratings upgraded Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research note on Tuesday, March 10th. Guggenheim set a $23.00 price target on Zevra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, March 10th. BTIG Research initiated coverage on Zevra Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Wall Street Zen upgraded Zevra Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, April 11th. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.00.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.